It is already known that individuals with heterozygous germline FAS variants have high risk for both non-Hodgkin and Hodgkin lymphomas, with incidences 14 and 51 times greater than the general population, respectively (34, 35). This evidence concerns the gene FAS and Hodgkins lymphoma.